# HELIX-1 (NCT04251715)

> mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

No report yet. It can be ordered.

- Drugs tested: mFOLFIRINOX plus floxuridine plus dexamethasone plus mFOLFIRI
- Indication: first-line unresectable liver-dominant intrahepatic cholangiocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04251715
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: OHSU Knight Cancer Institute
- Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
- Interventions: Dexamethasone; Floxuridine; Implanted Medical Device; Irinotecan; Leucovorin; Oxaliplatin; Quality-of-Life Assessment
- Enrollment: 5
- Primary outcome: Frequency of Abnormal Liver Function
- Primary outcome: Disease Control Rate (DCR) - During HAI+SYS

## Indexed commentary on HELIX-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=helix-1-nct04251715